Compares linvoseltamab, alone or with carfilzomib, against standard treatments for relapsed myeloma
Tests linvoseltamab, alone or with carfilzomib, in adults with relapsed or refractory multiple myeloma.
Plain-language title generated from the registry record
Registry title: A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Key facts
- Where
- Belo Horizonte, Curitiba, Joinville, Lages, Niterói, Porto Alegre, Ribeirão Preto, and São Paulo, BrazilSee the 10 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Which of these best describes your myeloma treatment so far?
- Have you ever taken lenalidomide (also called Revlimid), a tablet medicine for myeloma?
- Has a doctor told you that you have myeloma in the brain or in the fluid and membranes around the brain and spinal cord, now or in the past?
Source: NCT07222761, who can take part
Where in Brazil
- Cetus OncologiaBelo Horizonte, BrazilTaking people
- Hospital Erasto GaertnerCuritiba, BrazilTaking people
- Centro de Hematologia e OncologiaJoinville, BrazilTaking people
- ANIMILages, BrazilTaking people
- Oncomed Clínica OncológicaNiterói, BrazilTaking people
- Centro Gaúcho Integrado - Hospital Mae de DeusPorto Alegre, BrazilTaking people
- Hospital de Clinicas de Porto AlegrePorto Alegre, BrazilTaking people
- Unidade de Pesquisa Clinica (UPC); Hospital das Clinicas de Ribeirao Preto da Universidade de Sao PauloRibeirão Preto, BrazilTaking people
- AC Camargo Cancer CenterSão Paulo, BrazilTaking people
- Clinica Medica Sao GermanoSão Paulo, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Regeneron Pharmaceuticals
- Trial code
- NCT07222761EU 2024-519504-27-00
- Record updated
- 4 November 2026
- Original description
This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive Multiple Myeloma (MM) after at least 1 but no more than 3 prior therapies.Read full original descriptionShow less
An Open-Label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab Plus Carfilzomib Versus Standard of Care Combination Regimens in Patients With Relapsed/Refractory Multiple Myeloma
This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive Multiple Myeloma (MM) after at least 1 but no more than 3 prior therapies.
The aim of this study is to see if the safety and efficacy of linvoseltamab alone or in combination with carfilzomib can deliver better outcomes (deeper and longer responses that help extend life) than standard treatment options.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Inclusion: Participant with RRMM who received at least 1 but not more than 3 prior lines of therapy, which must have included treatment with lenalidomide and either a Protease Inhibitor (PI) or anti-CD38 monoclonal antibody; Eastern Cooperative Oncology Group (ECOG) performance status score ≤2; Confirmed progressive disease according to IMWG criteria during or after the most recent line of therapy.
Exclusion: Prior treatment with a T cell-based immunotherapy targeting BCMA, including BCMA-directed bispecific antibodies, Bispecific T-cell Engagers (BiTEs), and Chimeric Antigen Receptor (CAR) T cells. Antibody-drug conjugates targeting BCMA (eg, belantamab mafodotin) are not excluded; Diagnosis of plasma cell leukemia, symptomatic amyloidosis (including myeloma-associated amyloidosis), Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes); History of neurodegenerative condition, Progressive Multifocal Leukoencephalopathy (PML), or CNS movement disorder; NOTE: Other protocol defined inclusion/exclusion criteria apply; Known Central Nervous System (CNS) involvement of myeloma including meningeal involvement.